We assessed the value of urinary neopterin concentrations for prognosis of disease progression in HIV-1-infected patients. Sixty-eight anti-HIV-1 seropositive homosexuals with lymphadenopathy syndrome were tested for urinary neoptenn and T-celI subset counts in 1982-83, and the incidence rate at which they developed acquired immunodeficiency syndrome (AIDs) between then and May 1988 was evaluated.
Neopterin as a Predictive Marker for Disease Progression in Human Immunodeficiency
We assessed the value of urinary neopterin concentrations for prognosis of disease progression in HIV-1-infected patients. Sixty-eight anti-HIV-1 seropositive homosexuals with lymphadenopathy syndrome were tested for urinary neoptenn and T-celI subset counts in 1982-83, and the incidence rate at which they developed acquired immunodeficiency syndrome (AIDs) between then and May 1988 was evaluated.
Overall, 21 of 68 (30.9%) cases progressed to AIDS, with a yearly progression rate of 4-9%. The predictive value of urinary neopterin concentrations was higher (P = 0.0042) than that of CD4+ T-ceII counts (P = 0.015) or the C04+/ CD8+ T-cell ratio (P = 0.022). Counts of CD8+ T-cells failed to show predictive significance (P = 0.29). Similarly, multivariate-regression analysis indicated that neopterin concentrations and CD4+ T-cell numbers were significant copredictors. Produced by human macrophages activated by interferon gamma, neoptenn is thus a marker of macrophage activation via T cells. We conclude that these data demonstrate a correlation between the amount of T-cellmacrophage activation, as measured by urinary neopterin concentrations, and the progression of the disease.
Human immunodeficiency virus type 1 (HIV-1) is the causative agent for the acquired immunodeficiency syndrome (AIDS), which was first reported in the United States in 1981 (1).
Several reports have addressed the problem of early prediction of 11W-i-related disease progression. Low numbers of CD4+ T-helper/inducer cells and low ratios of CD4+ T-cell ratios, concomitantly with measurements of neopterin.
Materials and Methods

Patients:
The study population of 68 patients was enrolled in 1982 and the first half of 1983. These patients are a randomly chosen subset of an entire cohort described in detail earlier (2,9). All had 11W-i-associated lymphadenopathy syndrome and some had various constitutional symptoms. All were homosexual or bisexual men and were shown retrospectively to have been anti-HIV-1 seropositive already at their initial visit by ELISA (Abbott Laboratories, North Chicago, IL) confirmed by Western blot. 4 Assay methods: Neopterin was determined in first morning urine specimens by a reversed-phase "high-performance" liquid chromatography (HPLC) method described elsewhere (13), which allows simultaneous determination of urinary creatinine. Neopterin concentrations were related to creatinine values to compensate for physiological variations in the analyte concentrations in urine. Percentages of T-helper/inducer cells (CD4+) and Tsuppressor/cytotoxic cells (CD8+) were measured by mdirect immunofluorescence after reaction with OKT4 and OKT8 monoclonal antibodies, respectively (Ortho Diagnostic System, Inc., Raritan, NJ), followed by reaction with a fluorescein-conjugated anti-mouse immunoglobulin. All specimens were analyzed with a fluorescence-activated cell sorter (FACS-IV; Becton-Dickinson FACS Systems, Sunnyvale, CA) as described (14) .
Absolute numbers of these lymphocyte subsets were determined by multiplying the percentages of each subset by the absolute lymphocyte count. The ratio of T-helper/ inducer cells to T-suppressor/cytotoxic cells (CD4+/CD8+) is the percentage of the former divided by the latter. Statistical analyses: The cumulative incidence of AIDS was computed by the Product Limit approach (15) for all patients and separately for subgroups of patients. These subgroups were defined by splitting the group in two at the median for either neopterin or one of the T-cell variables. Differences of incidences between subgroups of patients were assessed by the generalized Wilcoxon test (16). Whether combinations of neopterin concentrations and T-cell data were significant co-predictors for progression to AIDS was tested by the multivariate Proportional Hazards model (17) . In this analysis the data were again treated as binary variables, dichotomized at the median values.
Results
Neopterin was measured and T cells were differentiated and counted for the patients with lymphadenopathy syndrome in 1982-83 (Table 1) . Neopterin concentrations were not correlated with either of the T-cell data (P >0.1, Spearinan rank correlation coefficients).
Of the 68 patients enrolled in this part of the study, 21 (3 1%) progressed towards AIDS from the initial testing to the end of May 1988. The cumulative frequency of cases developing overt AIDS was 7.4% (SE 2.9%) by one year after collection of specimens, 11.8% (SE 3.9%) after two years, 20.6% (SE 4.9%) after three years, and 27.9% (SE 5.3%) after four years. Figure 1 shows the cumulative incidences of AIDS cases among the subgroups of patients defined by T-cell variables and by neopterin concentrations. As illustrated, neopterin was the best single predictor for disease progression. An even slightly better discrimination was obtained by relating neopterin either to the CD4+/CD8+ ratio or to the CD4+ T-cell number alone. CD4+ T-cell number and the CD4+/CD8+ T-cell ratio are individually of similar but less discriminating power, whereas the number of CD8+ T cells does not discriminate significantly between cases progressing towards AIDS and those that do not. The suitability of the proportionality assumption has been checked graphically by making use of the "log minus log survival plot" (not shown).
A stepwise multivariate-regression analysis by the Proportional Hazards method shows that-among the variables CD8+ T-cell number, CD4+ T-cell number, CD4+/ CD8+ T-cell ratio, and neopterin-only
the combination CD4+ T-cell number and neopterin is jointly significant. The regression coefficients obtained are 1.58 (SE 0.52, P = 0.0008) for neopterin and 1.14 (SE 0.47, P = 0.011 1) for CD4+ T-cell number. From these coefficients we conclude that the risk for disease progression towards itms, adjusted for the CD4+ T-cell count, for a patient with a neopterin concentration higher than the median value is 4.9 times greater (95% confidence interval, 1.8 to 13.4) than for a patient with neopterin concentration below the median value. Similarly, the relative risk associated with low numbers of CD4+ T cells, adjusted for neopterin, is 3.1 (95% confidence interval: 1.3 to 7.8).
Discussion
The overall progression rate towards AIDS in the group of homosexuals studied was 21/68 (30.9%) during the fiveyear period, somewhat lower than the rates observed in other homosexual cohorts, e.g., from New York (18) . Most of our study patients were enrolled relatively early in their H1V infection, according to the date of onset of lymphadenopathy noted by the patient or his physician, whereas patients in the early cohorts from New York had been infected longer at the time of enrollment (the rate of progression appears to increase with increasing time since infection). The rate of progression to AIDS in our study is similar to those of cohorts in San Francisco and other cities except New York City.
As this study shows, reliable predictive information on H1V-i-related disease can be obtained by measuring neoptern without counting lymphocyte subsets. Univariate and multivariate analyses of AIDS incidence rates in subgroups of patients defined by neopterin or T-cell variables show that the predictive value ofneopterin concentrations in the studied patients was even higher than that of CD4+ T-cell counts or CD4+/CD8+ T-cell ratios. This agrees with results obtained in other groups ofHlV-1-infected patients, e.g., in homosexual men in Vienna, Austria (19), and in heterosexual intravenous drug addicts incarcerated in Innsbruck, Austria (10) . Interestingly, the predictive power of two composite variables, the ratios between neopterin concentrations and CD4+/CD8+ ratio, or CD4+ T-cell numbers, was even better, in agreement with a proposal of Crocchiolo et al. (20) . Thus, for these two combinations the high-risk group showed an overall progression rate towards AIDS of 17/34 (50.0%), in contrast to 4/34 (11.8%) in the low-risk group.
Neopterin is produced by human monocyte/macrophages upon stimulation with interferon gamma (21) . In various clinical conditions generally characterized by the involvement of T cells and macrophages, the measurement of neopterin provides a simple, noninvasive tool for assessing the activation state of the afferent side of cell-mediated immunity (22) . Recently, increased concentrations of circulating interferon gamma and a close correlation with neoptern concentrations were established in patients with 11W-i infection (23).
The application of neopterin measurement in 11W-irelated disease has recently been summarized (24) . In brief, increased concentrations of neopterin are seen early in the course of disease, usually before CD4+ T cells begin to decrease (25) . Anti-HIV-1 seropositive subjects usually show neopterin concentrations increased to a similar degree in patients with or without persistent generalized lymphadenopathy, whereas concentrations are significantly higher in patients with AIDS-related complex: the highest concentrations are seen in patients with full-blown
AIDS.
We conclude from these results, and also from several previous studies (10, 14, 24, 25 ) on neopterin in 11W-i infection, that activation of cell-mediated immune mechanisms appears to be common in infected patients and is significantly associated with more rapid progression towards the fully expressed disease. This agrees with several other reports that have shown the importance of immunological activation in vivo (11,24) as well as in vitro (26) .
From a practical point of view, neopterin measurement is easily done by HPLC or by commercially available radioimmunoassay (e.g., Neopterin RIAcid; Henning-Berlin, Berlin, F.R.G.) in urine, serum (27) , and other biological fluids such as cerebrospinal fluid (28). Thus measurement of neopterin offers a reliable alternative to more invasive methods for frequent judging of the clinical status of HIV-1-infected patients.
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